ERBB2 and gastric carcinoma: There are 11 ongoing clinical trials for breast, lung, and gastric carcinomas, including two phase III trials: NCT04924699 for HER2-positive unresectable locally advanced or metastatic breast cancer and NCT05754853 for HER-2-positive unresectable or advanced metastatic urothelial cancer.